• +1-646-491-9876
    • +91-20-67278686

    Search

    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017

    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017

    • Report Code ID: RW0001689389
    • Category Healthcare
    • No. of Pages 134
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

    Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 7, 1, 19, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
    - The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development
    A1M Pharma AB
    Alloksys Life Sciences BV
    Am-Pharma BV
    Angion Biomedica Corp
    Atox Bio Ltd
    Cellmid Ltd
    Complexa Inc
    DiaMedica Therapeutics Inc
    DURECT Corp
    Evotec AG
    Exponential Biotherapies Inc
    F. Hoffmann-La Roche Ltd
    G1 Therapeutics Inc
    Kringle Pharma Inc
    Mitotech SA
    NephroGenex Inc
    NeuroVive Pharmaceutical AB
    Nyken BV
    ProMetic Life Sciences Inc
    Quark Pharmaceuticals Inc
    Regulus Therapeutics Inc
    SBI Pharmaceuticals Co Ltd
    Spherium Biomed SL
    STATegics Inc
    Stealth BioTherapeutics Inc
    Thrasos Therapeutics Inc
    Torrent Pharmaceuticals Ltd
    Xigen SA
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles
    (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    A1M-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AB-103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BB-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    brimapitide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CAB-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CXA-10 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DM-199 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug for Kidney Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DUR-928 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EA-230 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    elamipretide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KP-100IT - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MG-53 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NOXD-21 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NVP-019 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NYK-1341 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PBI-4419 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Plastomitin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Pyridoxamine Dihydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    QPI-1002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    R-190 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Human Alkaline Phosphatase - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RLS-003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RMC-035 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RO-6839328 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SP-15016 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    STSE-15 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    THR-184 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TRC-160334 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vanadis-03 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones
    Featured News & Press Releases
    Feb 10, 2017: A1M Pharma has successfully conducted large scale manufacturing of the active substance in ROSGard and initiates GLP toxicology studies
    Jan 31, 2017: Angion Biomedica Phase 2 “GUARD” Clinical Trial of BB3 in Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study in Renal Transplant Recipients with Delayed Graft Function
    Jan 30, 2017: DURECT Announces Update on DUR-928 Development Program
    Dec 20, 2016: Silence Therapeutics Announces Quark Arbitration Resolution
    Dec 09, 2016: ROSGard shows renal protective effect during radiation therapy
    Nov 07, 2016: Stealth BioTherapeutics Announces Acceptance of Late-Breaking Clinical Trial Poster at American Society of Nephrology Kidney Week 2016
    Sep 19, 2016: Quark Pharmaceuticals to provide an update on kidney transplant drug QPI-1002
    Sep 13, 2016: A1M Pharma selects kidney protection in connection with cancer treatment as their first indication within acute kidney injury
    May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial
    Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury
    Apr 19, 2016: AM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design”
    Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002
    Feb 29, 2016: Thrasos Announces Promising Results for Phase II THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)
    Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928
    Dec 14, 2015: NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma BV, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Ltd, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Ltd, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Therapeutics Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corp, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Evotec AG, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Exponential Biotherapies Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitotech SA, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken BV, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Rediscovery Life Sciences, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Regulus Therapeutics Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed SL, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Stealth BioTherapeutics Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos Therapeutics Inc, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Xigen SA, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2017
    Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    A1M Pharma AB
    Alloksys Life Sciences BV
    Am-Pharma BV
    Angion Biomedica Corp
    Atox Bio Ltd
    Cellmid Ltd
    Complexa Inc
    DiaMedica Therapeutics Inc
    DURECT Corp
    Evotec AG
    Exponential Biotherapies Inc
    F. Hoffmann-La Roche Ltd
    G1 Therapeutics Inc
    Kringle Pharma Inc
    Mitotech SA
    NephroGenex Inc
    NeuroVive Pharmaceutical AB
    Nyken BV
    ProMetic Life Sciences Inc
    Quark Pharmaceuticals Inc
    Regulus Therapeutics Inc
    SBI Pharmaceuticals Co Ltd
    Spherium Biomed SL
    STATegics Inc
    Stealth BioTherapeutics Inc
    Thrasos Therapeutics Inc
    Torrent Pharmaceuticals Ltd
    Xigen SA

    Request for Sample

    Report Url https://www.reportsweb.com//Acute-Renal-Failure-(ARF)-(Acute-Kidney-Injury)---Pipeline-Review,-H1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//Acute-Renal-Failure-(ARF)-(Acute-Kidney-Injury)---Pipeline-Review,-H1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//Acute-Renal-Failure-(ARF)-(Acute-Kidney-Injury)---Pipeline-Review,-H1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments